Benzinga | Feb 4, 2021 08:50AM EST

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $200

Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $195 to $200.